|
NDUFB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.55031584528842E-15 |
| Normal-vs-Stage2 |
7.794500E-04 |
| Normal-vs-Stage3 |
1.77791115163473E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
5.396300E-02 |
| Stage1-vs-Stage3 |
6.223600E-02 |
| Stage1-vs-Stage4 |
2.28139999999266E-05 |
| Stage2-vs-Stage3 |
5.176300E-03 |
| Stage2-vs-Stage4 |
5.81199999999393E-05 |
| Stage3-vs-Stage4 |
2.115800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.50809999996693E-07 |
| Normal-vs-Asian |
9.70719948867327E-10 |
| Caucasian-vs-AfricanAmerican |
7.990800E-01 |
| Caucasian-vs-Asian |
7.228800E-01 |
| AfricanAmerican-vs-Asian |
9.919200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.99200722162641E-16 |
| Normal-vs-Female |
1.62669877568078E-12 |
| Male-vs-Female |
1.600390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.59883217776269E-12 |
| Normal-vs-Age(41-60Yrs) |
4.21884749357559E-14 |
| Normal-vs-Age(61-80Yrs) |
9.29690002759997E-09 |
| Normal-vs-Age(81-100Yrs) |
4.3822999995502E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.365000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.513400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.429000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.269600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.463800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.836600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.463000E-03 |
| Classical-VS-Follicular |
3.31960000043985E-07 |
| Classical-VS-Other |
7.471000E-01 |
| Classical-VS-Normal |
1.65578661892596E-12 |
| Tall-VS-Follicular |
2.58809995656861E-09 |
| Tall-VS-Other |
3.942000E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
6.896300E-02 |
| Follicular-VS-Normal |
1.697950E-03 |
| Other-VS-Normal |
2.005100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.11369818817298E-11 |
| Normal-vs-N1 |
1.62569957495862E-12 |
| N0-vs-N1 |
2.09429999999955E-05 |
|
|
